A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer.
Bolus
Breast cancer
Mastectomy
PMRT
Radiation therapy
Tissue compensator
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
04
06
2021
revised:
14
09
2021
accepted:
15
09
2021
pubmed:
27
9
2021
medline:
31
12
2021
entrez:
26
9
2021
Statut:
ppublish
Résumé
Bolus serves as a tissue equivalent material that shifts the 95-100% isodose line towards the skin and subcutaneous tissue. The need for bolus for all breast cancer patients planned for postmastectomy radiation therapy (PMRT) has been questioned. The work was initiated by the faculty of the European SocieTy for Radiotherapy & Oncology (ESTRO) breast cancer courses and represents a multidisciplinary international breast cancer expert collaboration to optimize PMRT. Due to the lack of randomised trials evaluating the benefits of bolus, we designed a stepwise project to evaluate the existing evidence about the use of bolus in the setting of PMRT to achieve an international consensus for the indications of bolus in PMRT, based on the Delphi method.
Identifiants
pubmed: 34563607
pii: S0167-8140(21)06735-9
doi: 10.1016/j.radonc.2021.09.012
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-121Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.